Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial

Karin Fjordén*, Sara Ekberg, Nevzeta Kuric, Karin E. Smedby, Ingemar Lagerlöf, Thomas S. Larsen, Judit M. Jørgensen, Peter de Nully Brown, Mats Jerkeman

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

7 Citationer (Scopus)
OriginalsprogEngelsk
TidsskriftBritish Journal of Haematology
Vol/bind196
Udgave nummer2
Sider (fra-til)437-440
Antal sider4
ISSN0007-1048
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
We thank all the patients and the participating centres for their contribution. We thank Gilead for contribution with research grant and supply of study drug idelalisib.

Citationsformater